查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1510433

溶瘤病毒免疫治疗市场- 按病毒类型（HSV、腺病毒、痘苗病毒、呼肠孤病毒）、应用（黑色素瘤、乳腺癌、前列腺癌）、给药途径（肿瘤内、静脉内）、最终用户- 全球预测2024 - 2032

Oncolytic Virus Immunotherapy Market - By Virus Type (HSV, Adenovirus, Vaccinia Virus, Reovirus), Application (Melanoma, Breast Cancer, Prostate Cancer), Route of Administration (Intratumoral, Intravenous), End-user - Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于该领域的研究和开发不断增加，2024 年至 2032 年全球溶瘤病毒免疫治疗市场的复合年增长率将达到 22.6%。溶瘤病毒免疫疗法是一种有前途的癌症治疗方法，涉及使用病毒选择性地靶向和杀死癌细胞，同时保护健康组织。最近在理解病毒与宿主相互作用、基因工程和免疫学方面取得的进展导致了更有效的溶瘤病毒的开发。

例如，2024 年 4 月，有人推测将免疫疗法与旨在攻击癌细胞的病毒相结合可能为治疗神经内分泌肿瘤（一种发病率不断增加的罕见癌症）提供一种有前景的方法。由迈阿密大学米勒医学院西尔维斯特综合癌症中心领导的一项正在进行的研究的数据在美国癌症研究协会会议上发表。

这些病毒经过改造可增强其肿瘤选择性特性并刺激免疫系统产生抗癌反应。随着正在进行的临床试验显示出有希望的结果以及几种溶瘤病毒疗法的批准，对此类治疗的需求正在增加，因为它们为改善癌症患者的治疗结果带来了希望。

溶瘤病毒免疫治疗产业的整体规模根据病毒类型、应用、给药途径、最终用途和地区进行分类。

腺病毒细分市场将在 2024 年至 2032 年实现突破性成长。腺病毒透过选择性地靶向和破坏癌细胞，同时不伤害健康细胞，在癌症治疗中显示出了前景。使用基于腺病毒的疗法的临床试验已证明在各种类型的癌症中取得了令人鼓舞的结果。基于腺病毒的免疫疗法刺激免疫系统识别和攻击癌细胞，提供了潜在有效的治疗选择。随着研究不断揭示基于腺病毒的疗法的全部潜力及其对抗癌症的有效性，溶瘤病毒免疫疗法市场对这些创新疗法的需求正在稳步增长。

2024年至2032年，肿瘤内领域的溶瘤病毒免疫治疗市场份额将出现显着的复合年增长率。这种有针对性的方法可以最大限度地减少全身副作用并提高治疗效果。临床试验已证明肿瘤内溶瘤病毒免疫疗法在多种癌症（包括黑色素瘤和晚期实体瘤）中的潜力。随着研究人员不断探索新的病毒载体和联合疗法，对肿瘤内溶瘤病毒治疗的需求不断增长。它们为个人化癌症治疗提供了一条有前途的途径，代表了癌症治疗的重大进步。

2024年至2032年，欧洲溶瘤病毒免疫治疗市场将呈现显着的成长速度。欧洲的临床试验和研究计画正在探索溶瘤病毒靶向和破坏癌细胞同时增强针对肿瘤的免疫反应的潜力。随着病毒工程和治疗策略的进步，欧洲医疗保健提供者热衷于采用溶瘤病毒免疫疗法，为患者提供更有效和个人化的治疗选择。这种不断增长的需求凸显了溶瘤病毒疗法在欧洲癌症治疗领域的重要性。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症发生率上升
      • 越来越关注联合疗法
      • 研发投资不断增加
      • 病毒工程不断进步
    • 产业陷阱与挑战
      • 免疫原性和治疗抗药性的发展
      • 与治疗相关的高成本和风险
  • 成长潜力分析
  • 管道分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按病毒类型，2021 - 2032 年

  • 主要趋势
  • 单纯疱疹病毒（HSV）
  • 腺病毒
  • 牛痘病毒
  • 新城疫病毒
  • 呼肠孤病毒
  • 其他病毒类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 瘤内
  • 静脉
  • 其他给药途径

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 黑色素瘤
  • 乳癌
  • 肺癌
  • 卵巢癌
  • 摄护腺癌
  • 其他应用

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 癌症研究机构
  • 门诊手术中心
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 10 章：公司简介

  • Amgen Inc.
  • Creative Biolabs
  • Daiichi Sankyo Company Limited
  • Genelux Corporation
  • Oncorus Inc.
  • Replismune Inc.
  • Siga Technologies
  • Sorrento Therapeutics Inc.
  • TILT Biotherapeutics
  • Viralytics Ltd.
简介目录
Product Code: 8770

Global Oncolytic Virus Immunotherapy Market will witness 22.6% CAGR between 2024 and 2032 due to increasing research and development in the field. Oncolytic virus immunotherapy, a promising approach in cancer treatment, involves using viruses to target and kill cancer cells selectively while sparing healthy tissue. Recent advancements in understanding virus-host interactions, genetic engineering, and immunology have led to the development of more effective oncolytic viruses.

For instance, in April 2024, it was speculated that combining immunotherapy with a virus designed to attack cancer cells may offer a promising approach to treating neuroendocrine tumors, a rare cancer with increasing incidence. Data from an ongoing study led by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine was presented at the American Association for Cancer Research Meeting.

These viruses are engineered to enhance their tumor-selective properties and stimulate the immune system to mount an anti-cancer response. With ongoing clinical trials showing promising results and the approval of several oncolytic virus therapies, the demand for such treatments is escalating as they offer hope for improved outcomes in cancer patients.

The overall Oncolytic Virus Immunotherapy Industry size is classified based on the virus type, application, route of administration, end-use, and region.

The adenovirus segment will record breakthrough growth over 2024-2032. Adenoviruses have shown promise in cancer treatment by selectively targeting and destroying cancer cells while leaving healthy cells unharmed. Clinical trials using adenovirus-based therapies have demonstrated encouraging results in various types of cancer. Adenovirus-based immunotherapies stimulate the immune system to recognize and attack cancer cells, offering a potentially potent treatment option. As research continues to uncover the full potential of adenovirus-based therapies and their effectiveness in combating cancer, the demand for these innovative treatments in the oncolytic virus immunotherapy market is increasing steadily.

The oncolytic virus immunotherapy market share from the intratumoral segment will register a notable CAGR from 2024 to 2032. Intratumoral therapy involves directly injecting oncolytic viruses into tumors, triggering a localized immune response against cancer cells. This targeted approach minimizes systemic side effects and enhances treatment efficacy. Clinical trials have demonstrated the potential of intratumoral oncolytic virus immunotherapy in various cancers, including melanoma and advanced solid tumors. As researchers continue to explore new viral vectors and combination therapies, the demand for intratumoral oncolytic virus treatments is growing. They offer a promising avenue for personalized cancer therapy and represent a significant advancement in cancer treatment.

Europe oncolytic virus immunotherapy market will exhibit a noteworthy growth rate from 2024 to 2032. As European countries increasingly prioritize innovative cancer therapies, oncolytic virus immunotherapy stands out as a promising approach. Clinical trials and research initiatives in Europe are exploring the potential of oncolytic viruses to target and destroy cancer cells while boosting the immune response against tumors. With advancements in viral engineering and treatment strategies, European healthcare providers are keenly adopting oncolytic virus immunotherapy to offer patients more effective and personalized treatment options. This growing demand underscores the significance of oncolytic virus therapies in the European cancer treatment landscape.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of cancer
      • 3.2.1.2 Increasing focus towards combination therapies
      • 3.2.1.3 Rising R&D investments
      • 3.2.1.4 Growing advancements in viral engineering
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Development of immunogenicity and resistance to the treatment
      • 3.2.2.2 High cost and risk associated with the treatment
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Herpes simplex virus (HSV)
  • 5.3 Adenovirus
  • 5.4 Vaccinia virus
  • 5.5 Newcastle disease virus
  • 5.6 Reovirus
  • 5.7 Other virus types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Intratumoral
  • 6.3 Intravenous
  • 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Melanoma
  • 7.3 Breast cancer
  • 7.4 Lung cancer
  • 7.5 Ovarian cancer
  • 7.6 Prostate cancer
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Hospitals & clinics
  • 8.3 Cancer research institutes
  • 8.4 Ambulatory surgical centers
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Amgen Inc.
  • 10.2 Creative Biolabs
  • 10.3 Daiichi Sankyo Company Limited
  • 10.4 Genelux Corporation
  • 10.5 Oncorus Inc.
  • 10.6 Replismune Inc.
  • 10.7 Siga Technologies
  • 10.8 Sorrento Therapeutics Inc.
  • 10.9 TILT Biotherapeutics
  • 10.10 Viralytics Ltd.